



## **PROFESSIONAL EXPERIENCE**

---

### **ACADEMIC**

**Professor** **November 1985 – July 2015**

**The University of Tennessee Health Science Center, Memphis, TN**

Spearheaded basic and translational education, training, and research with UTHSC, Memphis community, and global academic and industry collaborators.

- Designed and lead the Vascular Biology Center of Excellence with achieving a >10-fold ROI
- Published more than 120 peer-reviewed publications and 130 abstracts and invited speaker to more than 200 institutions, scientific meetings, and industry-sponsored events
- Organized the TN-AR-MS Clinical Research Consortium to facilitate collaborative clinical investigation among academic and private practice cardiologists in tri-state area
- Established UTHSC translational research grants to encourage collaborative translational research between PhD and MD faculty
- Received research and training grants from NIH and the AHA including the Established Investigator Award
- Served as KOL to small, mid-size and large pharmaceutical companies and received multimillion dollars of funding for investigator-initiated studies and industry contracts
- Served as translational liaison and team leader to provide scientific, translational, and project/product expertise across a variety of departments, colleges, and programs.
- Provided scientific / translational expertise and project management for programs related to hemostasis and thrombosis and vascular biology
- Secondary Appointments as Professor, The Department of Microbiology, Immunology and Biochemistry; Professor in the Department of Surgery; Professor of the Joint Program of Biomedical Engineering, The University of Memphis and UTHSC.
- Member, Graduate Faculty, UTHSC
- Member, Faculty Senate

**Clinical Professor** **July 2015 – September 2021**  
**Department of Internal Medicine**  
**The University of Tennessee Health Science Center, Memphis, TN**

**Professor** **October 2021- Present**  
**College of Graduate Health Sciences**  
**The University of Tennessee Health Science Center, Memphis, TN**

**CONSULTANT and ADVISOR**

**Pharmaceutical, Device, Biotechnology**

**1990 – Present**

**KOL in Thrombosis and Hemostasis**

- Advises pharmaceutical and device industry on relevant biomarkers and mechanism of action assessments to evaluate product effectiveness and clinically relevant on- and off-target effects
- Recommends clinical-site amenable sample processing or on-site testing for esoteric biomarkers; lab manual review
- Collaborates with industry to identify laboratory services companies that can provide pharmacodynamic or biomarker testing or assay development for clinical trial sample testing
- Reviews PD data generated in vitro or ex vivo; assist in manuscript or abstract preparation or presentations at investigator, national or international meetings
- Serves on advisory or KOL strategic boards

**PRIVATE INDUSTRY**

**Chief Scientific Officer , Global  
Managing Executive Officer US  
Executive Leadership Team, Global  
MLM Medical Labs, LLC**

**July 2020 - December 2022  
July 2020 - April 2022  
July 2020 – December 2022**

Leads the identification, development, management, and expansion of translational science technologies and resources at a global level.

- Evaluates top pharmaceutical companies' pipelines to identify biomarker applications and extrapolates from multiple resources to create and deliver strategic plans for clients
- Provides leadership in the development of the global company's statement of vision, mission, and goals, and the corresponding strategies, plans, and budgets to achieve them
- Evaluate market trends, provides competitive feedback, and leads the development of business models to support the launch of MLM Medical Labs services
- Identifies and develops collaborations with key pharma partners to facilitate the development of new services including assays that would enable monitoring of new drug therapies
- Leads the development of novel on-site training methods for laboratories, CROs, and clinical sites conducting clinical trials
- Provides business development insight to MLM Medical Labs project teams, ensures client's needs are addressed, and manages key client expectations given project and timeline constraints
- Collaborates with the Executive Management team members to develop and implement plans for the operational infrastructure of systems, processes and personnel designed to accommodate the growth objectives of the global company

*Minority Ownership in MLM Medical Labs, LLC*

**Founder and CEO/President  
CirQuest Labs, Memphis, TN**

**October 2008 – July 2020**

Leads the identification, development, management, and expansion of translational science technologies and resources.

- Evaluates top pharmaceutical companies' pipelines to identify biomarker applications and extrapolates from multiple resources to create and deliver strategic plans for clients
- Provides leadership in the development of the company's statement of vision, mission, and goals, and the corresponding strategies, plans, and budgets to achieve them
- Evaluate market trends, provides competitive feedback, and leads the development of business models to support the launch of CirQuest Labs services

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

- Identifies and develops collaborations with key pharma partners to facilitate the development of new services including assays that would enable monitoring of new drug therapies
- Leads the development of novel on-site training methods for laboratories, CROs, and clinical sites conducting clinical trials
- Provides business development insight to CirQuest Labs project teams, ensures client's needs are addressed, and manages key client expectations given project and timeline constraints
- Collaborates with the Executive and Upper Management teams to develop and implement plans for the operational infrastructure of systems, processes and personnel designed to accommodate the growth objectives of the company
- Drives the company to achieve and surpass revenues, profitability, cash flow and business objectives
- Serves as a liaison to the public, government, affiliated organizations, and other stakeholders

*Successful merger and acquisition July 2020 with MLM Medical Labs, LLC*

**Co-Founder**

**September 2007 - Present**

**Ariste Medical, LLC**

Lead the IP and technological development of drug-device combination products

- Co-led the founding, organization, and seed stage funding of Ariste Medical, LLC
- Responsible for technology and product early development of drug-device combination product
- Drives IP development
- Provides leadership as member of Board of Managers
- Investor
- Board of Managers

*Minority ownership in Ariste Medical, LLC*

**Co-Founder and CEO**

**Agile Biomedical, Inc. (holding company)**

**TEACHING EXPERIENCE**

---

<b>Lecturer, Cell Biology</b> UTHSC	2012 - 2014
<b>Lecturer, Cardiology Fellows Conference</b> UTHSC	2009 – 2016
<b>Speaker's Bureau</b> Pharmaceutical Industry	2003 – 2016

**SCIENTIFIC RESEARCH EXPERIENCE**

---

<b>Professor, University of Tennessee Health Science Center</b>	1985-present
<b>Leon Journey Fellow, St. Jude Children's Research Hospital, Memphis,</b>	1983-1985
<b>University of Tennessee Health Science Center, Memphis: Doctoral Studies</b> Isolation and Purification of Platelet GPIIb-IIIa Trainee at St. Jude Children's Research Hospital, Memphis, TN and the Gladstone Foundation Laboratories, San Francisco, CA	1980 -1983

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

**University of Memphis, Memphis, TN: Master of Science Studies** 1976-1978  
*Wall-softening of *Chlamydomonas eugametos**

**University of Tennessee, Knoxville, TN: Undergraduate Research** 1974-1976

**OTHER PROFESSIONAL EXPERIENCE**

---

**Leon Journey Fellow, St Jude Children's Research Hospital** 2009 - 2012

**NIH Ad hoc Scientific Review Panel** 2003 - present

**Consultant, Hematology and Pathology Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration** 2005 - present

**Advisory Boards, Pharmaceutical Industry, Academic Institutions** 2001- present

**EDUCATION**

---

**Doctor of Philosophy in Biochemistry** 1980-1983  
The University of Tennessee Health Science Center

**Master of Science in Cell Biology** 1976-1978  
University of Memphis, Memphis, TN

**Bachelor of Arts in Botany, Biology minor** 1973-1976  
University of Tennessee, Knoxville, TN

**TRAINING**

---

**CITI Human Research** **Completed** 07 June 2019; **Expiration** 06 Jun 2022  
Human Research and RCR

**International CPR Institute, Inc.** **Completed** 14 Dec 2020; **Expiration** 14 Dec 2021  
Bloodborne Pathogens Course

**The Global Health Network** **Completed** 21 February 2020  
Introductory to Good Clinical Laboratory Practices

**Cont'd**

GCLP: Organization and Personnel **Completed** :15 November 2020

GCLP: Facilities, Equipment, Materials and Reagents

GCLP: Standard Operating Procedures & Analytical Plan

GCLP: Method & Systems Validation

GCLP: Quality Management

GCLP: Sample Management, Conduct of the Work, Data Recording, and Data Reporting

**Internal Training**

**BSL-2 and BSC Training**

**Completed:** 01 Feb 2021

**PUBLICATIONS AND ABSTRACTS**

---

**Original Articles:**

1. Phillips, D.R., **Jennings, L.K.**, and Edwards, H.H. Identification of membrane proteins mediating the interaction of human platelets. *J Cell Biol* 86: 77-86, 1980.
2. Phillips, D.R., **Jennings, L.K.**, and Prasanna, H.R. Ca<sup>2+</sup>-mediated association of glycoprotein G (thrombin-sensitive protein, thrombospondin) with human platelets. *J Biol Chem* 255: 11629-11632, 1980.
3. **Jennings, L.K.**, Fox, J.E.B., Edwards, H.H., and Phillips, D.R. Changes in the cytoskeletal structure of human platelets following thrombin activation. *J Biol Chem* 256: 6927-6932, 1981.
4. **Jennings, L.K.**, and Phillips, D.R. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. *J Biol Chem* 257: 10458-10466, 1982.
5. Phillips, D.R., Fujimura, K., **Jennings, L.K.**, Parise, L., Fitzgerald, L., and Fox, J.E.B. Calcium regulation of glycoproteins IIb and III in human platelet membranes. *Ann NY Acad Sci* 416: 166-175, 1983.
6. **Jennings, L.K.**, Phillips, D.R., and Walker, W.S. Monoclonal antibodies to human platelet membrane glycoprotein IIb<sub>β</sub> that initiate distinct platelet responses. *Blood* 65: 1112-1119, 1985.
7. **Jennings, L.K.**, Brown, L.K., and Dockter, M.E. Quantitation of Protein 3 content in circulating erythrocytes at the single cell level. *Blood* 65: 1256-1262, 1985.
8. **Jennings, L.K.**, Ashmun, R.A., Wang, W.C., and Dockter, M.E. Analysis of human platelet glycoproteins IIb and IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry. *Blood* 68: 173-179, 1986.
9. Singer, J., **Jennings, L.K.**, Jackson C., Dockter, M.E., Morrison, M., and Walker, W.S. Erythrocyte homeostasis: Antibody mediated recognition of the senescent state by macrophages. *PNAS* 83: 5498-5501, 1986.
10. Loftus, J.C., Plow, E.F., **Jennings, L.K.**, and Ginsberg, M.H. Alternative proteolytic processing of platelet GPIIb. *J Biol Chem* 263: 11025-11028, 1988.
11. Jackson, C.W., and **Jennings, L.K.** Heterogeneity of fibrinogen receptor expression on platelets activated in normal plasma with ADP. Analysis by flow cytometry. *Br J Hematol* 72: 407-414, 1989.
12. **Jennings, L.K.**, Dockter, M.E., Wall, C.D., Fox, C.F, Kennedy, D.M. Calcium mobilization in human platelets using indo-1 and flow cytometry. *Blood* 74: 2674-2680, 1989.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

13. **Jennings, L.K.**, Fox, C.F., Kouns, W.C., McKay, C.P., Ballou, L.R., and Schultz, H.E. The activation of human platelets mediated by anti-human platelet p24/CD9 monoclonal antibodies. *J Biol Chem* 265: 3815-3822, 1990.
14. Kouns, W.C., Wall, C.D., White, M.M., Fox, C.F., and **Jennings, L.K.** A conformation dependent epitope of human platelet glycoprotein IIIa. *J Biol Chem* 265: 20594-20601, 1990.
15. **Jennings, L.K.**, Wang, W.C., Jackson, C.W., Fox, C.F., and Bell, A. Hemostasis in Glanzmann's thrombasthenia (GT): GT platelets interfere with the aggregation of normal platelets. *Am J Ped Hem Onc* 13(1): 84-90, 1991.
16. Rubinstein, E., Kouns, W.C., **Jennings, L.K.**, Boucheix, C., and Carroll, R.C. Interaction of two GPIIb/IIIa monoclonal antibodies with platelet Fc receptor (Fc $\gamma$ RII). *Br J Haematol* 78 (1): 80-86, 1991.
17. Lanza, F., Wolf, D., Fox, C.F., Kieffer, N., Seyer, J.M., Fried, V.A., Coughlin, S.R., Phillips, D.R., and **Jennings, L.K.** cDNA cloning and expression of platelet p24/CD9: Evidence for a new family of multiple membrane spanning proteins. *J Biol Chem* 266 (16): 10638-10645, 1991.
18. Kouns, W.C., and **Jennings, L.K.** Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor. *Thromb Res* 63: 343-354; 1991.
19. Kouns, W.C., Fox, C.F., Lamoreaux, W.J., Coons, L.B., and **Jennings, L.K.** The effect of glycoprotein IIb-IIIa receptor occupancy on the cytoskeleton of resting and activated platelets. *J Biol Chem* 266 (21): 13891-13900, 1991.
20. Kouns, W.C., Newman, P.J., Puckett, K.J., Miller, A.A., Wall, C.D., Fox, C.F., Seyer, J.M., and **Jennings, L.K.** Further characterization of the loop structure of platelet glycoprotein IIIa: Partial mapping of functionally significant epitopes. *Blood* 78 (12): 3215-3223, 1991.
21. White, M.M., Foust, J.T., Mauer, A.M., Robertson, J.T., and **Jennings, L.K.** Assessment of lumiaggregometry for research and clinical laboratories. *Thromb Haemost* 67(5): 572-577, 1992.
22. White, M.M., Siders, L., **Jennings, L.K.**, and White, F.L. The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia. *Thromb Haemost* 68(1): 88, 1992.
23. Kouns, W.C., Kirchhofer, D., Hadvary, P., Edenhofer, A., Weller, T., Pfenninger, G., Baumgartner, H.R., **Jennings, L.K.**, and Steiner, B. Reversible conformational changes induced in GPIIb-IIIa by a potent and selective peptidomimetic inhibitor. *Blood* 80(10): 2539-2547, 1992.
24. **Jennings, L.K.**, White, M.M., Sauer, C.M., Mauer, A.M., and Robertson, J.T. Cocaine-induced platelet defects. *Stroke* 24: 1352-1359, 1993.
25. **Jennings, L.K.**, Crossno, Jr., J.T., Fox, C.F., White, M.M., and Green, C.A. Platelet p24/CD9, A member of the tetraspanin family of proteins. *Ann N Y Acad Sci* 714: 175-184, 1994.
26. Kouns, W.C., Steiner, B., Kunicki, T.J., Moog, S., Jutzi, J., **Jennings, L.K.**, Cazenave, J.P., and Lanza, F. Activation of the fibrinogen binding site on platelets isolated from a patient with the Strasbourg I variant of Glanzmann's thrombasthenia. *Blood* 84: 1108-1115, 1994.
27. Slack, S.M., **Jennings, L.K.**, and Turitto, V.T. Platelet size distribution measurements as indicators of shear stress induced platelet aggregation. *Annals Biomed Eng* 22(6): 653-659, 1994.
28. Wall, J.E., Buijs-Wilts, M., Arnold, J.T., Wang, W., White, M.M., **Jennings, L.K.**, and Jackson, C.W. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granules. *Brit J Haematol* 89: 380-385, 1995.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

29. **Jennings, L.K.**, White, M.M., and Mandrell, T.D. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: Observed differences in GPIIb-IIIa functional activity. *Thromb Haemost* 74(6): 1551-1556, 1995.
30. **Jennings, L.K.**, Slack, S.M., Wall, C.D., and Heath, T.L. Immunological comparisons of Integrin  $\alpha$ IIb $\beta$ 3 (GPIIb-IIIa) expressed on platelets and human erythroleukemia cells: Evidence for cell specific differences. *Blood Cells, Molecules and Diseases* 22(3) Feb 15: 23-35, 1996.
31. White, M.M., **Jennings, L.K.**, Siders, L., and White, F.L. Effect of heparin removal filter (letter). *Amer J Path* 105: 372; 1996.
32. Mondoro, T.H., Wall, C.D., White, M.M., and **Jennings, L.K.** Selective induction of a GPIIIa LIBS by fibrinogen and von Willebrand Factor. *Blood* 88: 3824-3830, 1996.
33. Brisson, C., Azorsa, D.O., **Jennings, L.K.**, Moog, S., Cazenave, J.P., and Lanza, F. Co-localization of CD9 and GPIIb-IIIa (alphaIIb/beta3 integrin) on activated platelet pseudopods and  $\alpha$ -granule membranes. *Histochem J* 29: 153-165, 1997.
34. Phillips, D.R., Teng, W.S., Arfsten, A., Nanizzi-Alaimo, L., White, M.M., Longhurst, C., Shattil, S.J., Randolph, A., Jakubowski, J.A., **Jennings, L.K.**, and Scarborough, R.M. Effect of Ca<sup>++</sup> on Integrilin™ GPIIb-IIIa interactions: Enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. *Circulation* 96: 1488-1494, 1997.
35. Wall, C. D., Conley, P.B., Armendariz-Borunda, J., Sudarshan, C., Wagner, J.E., Raghov, R., and **Jennings, L.K.** Expression of  $\alpha$ IIb $\beta$ 3 Integrin (GPIIb-IIIa) in myeloid cell lines and normal CD34+/CD33+ bone marrow cells. *Blood Cells, Molecules and Diseases* 23 (18) 361 – 376, 1997.
36. **Jennings, L.K.**, and White, M.M. Expression of LIBS (Ligand Induced Binding Sites) on GP IIb-IIIa complexes and the effect of various inhibitors. *Am Heart J* 135: S179-183, 1998.
37. Jackson, D.E., White, M.M., **Jennings, L.K.**, and Newman, P.J. A Ser162-Leu mutation within glycoprotein (GP) IIIa (integrin  $\beta$ 3) results in an unstable  $\alpha$ IIb $\beta$ 3 complex that retains partial function in a novel form of Type II Glanzmann's thrombasthenia. *Thromb Haemost* 80: 42-48, 1998.
38. Longhurst, C.M., White, M.M., **Jennings, L.K.** A CD9,  $\alpha$ IIb $\beta$ 3, integrin-associated protein, and GPIb/V/IX complex on the surface of human platelets is influenced by  $\alpha$ IIb $\beta$ 3 conformation states. *Eur J Biochem* 263(1):104-111, 1999.
39. Cook, G.A., Wilkinson D.I., Crossno, J.T., Jr., Raghov, R., and **Jennings, L.K.** The tetraspanin CD9 influences the adhesion, spreading and pericellular fibronectin matrix assembly of Chinese hamster ovary (CHO) cells on human plasma fibronectin. *Exp Cell Res* 251:356-371, 1999.
40. **Jennings, L.K.**, Haga, J.H., and Slack, S.M. Differential induction of a LIBS induced by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. *Thromb Haemost* 84:1095-1102, 2000.
41. Mondoro, T.H., White, M.M., **Jennings, L.K.** Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. *Blood* 96(7):2487-2495, 2000.
42. Giugliano, R.P., McCabe, C.H., Sequeira, R.F., Frey, M.J., Henry, T.D., Piana, R.N., Tamby, J.F., Jensen, B.K., Nicolas, S.B., **Jennings, L.K.**, Wise, R.J., Braunwald, E. First report of an intravenous and oral GP IIb/IIIa Inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and TIMI 15B trials. *Am Heart J* 140(1):80-93, 2000.
43. Madan, M., Berkowitz, S.D., Christie, D.J., **Jennings, L.K.**, Smit, A.C., Sigmon, K.N., Glazer, S., Tchong, J.E. Rapid assessment of glycoprotein IIb-IIIa blockade using the platelet function analyzer (PFA-100) during percutaneous coronary intervention. *Am Heart J* 141(2):226-233, 2001.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

44. Gilchrist, I.C., O'Shea, J.C., Kosoglou, T., **Jennings, L.K.**, Lorenz, T.J., Kitt, M.M., Tcheng, J.E. Pharmacodynamics and pharmacokinetics of higher dose, double-bolus eptifibatide in percutaneous coronary Intervention. *Circ* 104:406-411, 2001.
45. Tardiff, B.E., **Jennings, L.K.**, Harrington, R.A., Gretler, D., Vorcheimer, D.A., Eisenberg, P.R., Lincoff, M.A., Labinaz, M., Joseph, D.M., McDougal, M.F., Kleiman, M.S. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: Prospective analysis from the Pursuit Trial. (Tardiff and Jennings are co-first authors) *Circ* 104:399-405, 2001.
46. Tcheng, J.E., Talley, J.D., O'Shea, J.C., Gilchrist, I.C., Kleiman, N.S., Grines, C.L., Davidson, C.J., Lincoff, A.M., Califf, R.M., **Jennings, L.K.**, Kitt, M.M., and Lorenz, T.J. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). *Am. J. Card.* 88(10): 1097-1102, 2001.
47. **Jennings, L.K.**, Jacoski, M.V., and White, M.M. The pharmacodynamics of parenteral glycoprotein IIb-IIIa Inhibitors. *J Intervent Cardiol*, 15(1):45-60, 2002.
48. Yellaturu, C.R., Ghosh, S.K., Rao, R.K., **Jennings, L.K.**, Hassid, A., Rao, G.N. A potential role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced cell proliferation. *Biochemical Journal* 368(Pt1):183-190, 2002.
49. Zhang, C., Yang, J., Feng, J., and **Jennings, L.K.** Short-term administration of bFGF enhances coronary collateral development without exacerbating atherosclerosis and balloon injury induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction. *J Lab Clin Med* 140(2):119-125, 2002.
50. Longhurst, C.M., Jacobs, J., White, M.M., Crossno, Jr., J.T., Fitzgerald, D.W., Bao, J., Fitzgerald, T., Raghov, R., and **Jennings, L.K.** Chinese hamster ovary cell motility to fibronectin Is modulated by the second extracellular loop of CD9: Identification of a putative fibronectin binding site. *J. Biol. Chem.* 277(36):32445-32452, 2002.
51. Cook, G. A., Longhurst, C., Grgurevich, S., Cholera, S., Crossno J.T., Jr., and **Jennings, L.K.** Identification of CD9 extracellular domains important in regulation of CHO cell adhesion to fibronectin and fibronectin pericellular matrix assembly. *Blood* 100(13):4502-4511, 2002.
52. Yellaturu, C.R., Ghosh, S.K., Rao, R.K., **Jennings, L.K.**, Hassid, A. and Rao, G.N. A potential role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced cell proliferation. *Biochem J* 368:183-190, 2002.
53. Haga, J.H., Slack, S.M. and **Jennings, L.K.** Inhibition of shear stress induced platelet aggregation (SIPA) and phosphotyrosine signaling by GPIIb-IIIa antagonists. *Ann. Biomed Eng* 30:1262-1272, 2002. Additionally selected for publication in the *Virtual Journal of Biological Physics Research*. January 1, 2003.
54. Haga, J.H., Slack, S.M. and **Jennings, L.K.** Comparison of shear-stress-induced platelet microparticle formation and phosphatidylserine expression in the presence of  $\alpha$ IIb $\beta$ 3 antagonists. *J. Cardiovas. Pharmacol* 41(3):363-71, 2003.
55. Bhanoori, M., Yellatura, C.R., Ghosh, S.K., Hassid, A.V., **Jennings, L.K.** and Rao, G.N. Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders It proapoptotic via activation of STATS and p53 and induction of expression of caspase 1 and p21<sup>waf1/cip1</sup>. *Oncogene* 22(1):117-30, 2003.
56. Grgurevich, S. Krishnan, R., White, M.M., and **Jennings, L.K.** Role of in-vitro cholesterol depletion in mediating human platelet aggregation. *J. Thromb Haemost*, 1;576-586, 2003.



**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

57. Zhang, C., Yang, J., Jacobs, J.D., and **Jennings, L.K.** Interaction of MPO with vascular NAD(H)P oxidases derived ROS in the vascular wall and its roles in vascular diseases: implications for vascular diseases. *Am. J. Physiol. Heart Circ. Physiol.* 285:H2563-H2572, 2003.
58. Lu, Y., Beheshti, B., Zhang, J., and **Jennings, L.K.** Characterization of a novel apoptosis inducing gene and its application in prostate cancer gene therapy. *Mol. Ther.* 7:17, 2003.
59. Lu, Y. Beech, D.J., and **Jennings, L.K.** p16 inhibits breast cancer angiogenesis by downregulating VEGF signaling pathway. *Proc. Amer. Assoc. Can. Res.* 44:697-698, 2003.
60. Lu, Y., Zhang, J., Beech, D.K., Myers, L.K. and **Jennings, L.K.** p16 downregulates VEGF and inhibits angiogenesis in breast cancer cells. *Cancer Ther.* 1:143-151, 2003.
61. Saucedo, J.F., Wolford, D.C., Cook, S.L., Ramanathan, K.B., Garza, L., Matin, Z., McGrew, F.A., Jacoski, M.V., **Jennings, L.K.** Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl In patients undergoing coronary Intervention-The TAM1 Study. *Am. J. Card.*, 93 (10) 1270-82, 2004.
62. Zhang, C., Yang, J., and **Jennings, L.K.** Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery. *Am J Physiol.* 287: H659-H666, 2004.
63. Gibson, C.M., **Jennings, L.K.**, Murphy, S.A., Lorenz, D.P., Giugliano R.P., Harrington, R.A., Cholera, S., Krishnan, R., Califf, R.M., Braunwald, E. Association between platelet receptor occupancy after eptifibatide (Integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment resolution among patients with ST-segment elevation myocardial infarction. *Circ.* 110:679-84, 2004.
64. Zhang, C., Yang, J and **Jennings, L.K.** Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated, vascular non-leukocyte-derived reactive oxygen species. *Diabetes* 53:2950-9, 2004.
65. Saucedo J.F., Lui H.K., Garza L., Guerra G.J., Jacoski, MV and **Jennings, L.K.** Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: The TAM2 Study. *J Thromb Thrombolysis*, 18(2), 67-74, 2004.
66. He B., Liu L., Cook G.A., Grgurevich S., **Jennings L.K.**, and Zhang X.A. Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin  $\alpha 6$ -mediated cell adhesion. *J. Biol. Chem.*, 2004 Nov 19 [Epub ahead of print], 280 (5): 3346-54, 2005.
67. White M.M., Krishnan R., Kueter T.J., Jacoski M.V., and **Jennings L.K.** The use of the point of care Helena ICHOR/Plateletworks<sup>®</sup> and the Accumetrics Ultegra<sup>®</sup> RPFA for assessment of platelet function with GPIIb-IIIa antagonists. *J Thromb Thrombolysis*, 18(3), 163-169, 2004.
68. Liu J, Jackson CW, Gruppo RA, **Jennings LK**, and Gartner TK. The beta 3 subunit of the integrin  $\alpha$ IIb $\beta$ 3 regulates  $\alpha$ IIb-mediated outside-in signaling. *Blood* 105:4345-52, 2005.
69. Cagiannos, C, Abul-Khoudoud, O.R., DeRijk, W., Shell, D.H., **Jennings, L.K.**, Tolley E., Handorf C.R., and Fabian T.C. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. *J Vasc Surg*, 42:980-8, 2005.
70. **Jennings, L.K.** Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. *Expert Opin Drug Metab Toxicol.* 1(4); 727-37.
71. Gibson, C.M., Morrow, D.A., Murphy, S.A.; Palabrica, T.M., **Jennings, L.K.**, Stone, P.H. Lui, H.H., Bulle, T., Lakkis, N., Kovach, R., Cohen, D.J., Fish, P., McCabe, C.H., and Braunwald, E. for the TIMI Study Group. A randomized trial to evaluate the relative PROTECTION against post-PCI

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

microvascular dysfunction, ischemia and inflammation among anti-platelet and anti-thrombotic agents: The PROTECT- TIMI 30 Trial. *JACC*, 47, 2364-73, 2006.

72. Yang J., Ji R., Cheng Y., Sun J.Z., **Jennings L.K.**, and Zhang C. L-arginine chlorination results in the formation of a non-selective nitric oxide synthase inhibitor. *J. Pharmacol Exp Ther* 318:1044-9, 2006; May22 [Epub ahead of print].
73. Gibson C.M., Karpaliotis D., Kosmidou .I, Murphy S. A., Kirtane A.J., Budiu D., Ray K.K., Hermann H.C., Lakkis N., Kovach R., French W., Blankenship J., Lui H. H., Palabrica T., **Jennings L. K.**, Cohen D., Morrow D. A., TIMI Study Group. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. *Am J Cardiol* 97: 1473-77, 2006.
74. Gibson,C.M., Kirtane A.J., Morrow D.A, Palabrica T.M., Murphy S.A., Stone P.H., Scirica B.M., **Jennings L.K.**, Herrmann H.C., Cohen D.J., McCabe C.H., Braunwald E., TIMI Study Group. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents- Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). *Am Heart J.* 2006 Oct; 152(4):756-61.
75. Dyke, C.M., **Jennings, L.K.**, Maier, G., Andreou, C., Daly, R., and Tamberella, M.R. Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass. *J. Cardiovasc Pharmacol Ther.* 12:54-60, 2007.
76. Li, J.S., Yow, E., Berezny, K.Y., Bokesch, P.M., Takahashi, M., Graham, T.P., Jr., Sanders, S.P., Sidi, D., Bonnet, D., Ewert, P., **Jennings, L.K.**, Michaelson, A.D., PICOLO Investigators. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On clopidogrel (PICOLO) trial. *Circ.* 117(4): 553-9, 2008.
77. Kotha, J., Longhurst, C.M., Appling, W., and **Jennings, L.K.** Tetraspanin CD9 regulates beta1 integrin activation and enhances cell motility to fibronectin via a PI3-kinase-dependent pathway. *Exp Cell Res.* 314(8):1811-22, 2008.
78. Kotha, J., Zhang, C., Longhurst, C.M., Lu, Y., Jacobs, J., Baker, B., Cheng, Y., and **Jennings, L.K.** Relevance of tetraspanin CD9 in vascular smooth muscle cell injury phenotypes: A novel target for the prevention of neointimal hyperplasia. *Arteriosclerosis.* 2008 Aug 8. [Epub ahead of print], 203(2): 377-86, 2009.
79. Speich, H., Grgurevich, S., Kueter, T., Earhart, A., Slack, S., and **Jennings, L.K.** Platelets undergo phosphorylation of syk at Y525/526 and Y352 in response to pathophysiological shear stress, *Amer J Physiol.*, 2008 Aug 20. [Epub ahead of print].
80. Becker, R.C., Moliterno, D.J., **Jennings, L.K.**, Pieper, K.S., Pei,J., Niederman, A, Ziada, KD, Berman, G, Strony J., Joseph, D., Mahaffey, K.W., van de Werf, F., Veltri, E., Harrington, R.A. for the TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. *Lancet*, 373:919-28, 2009.
81. Angiolillo, D.J., Bhatt, D.L., Gurbel, P.A., and **Jennings, L.K.** Advances in anti-platelet therapy: Agents in clinical development. *Am J Cardiol.* Feb 2;103(3 Suppl):40A-51A, 2009.
82. **Jennings, L.K.** Role of Platelets in Atherothrombosis. *Am J Cardiol.* Feb 2; 103(3 Suppl):4A-10A, 2009.
83. Speich, H.E., Earhart, A.D., Hill, S.N., Cholera, S., Kueter, T.J., White, M.M., and **Jennings, L.K.** Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab. *J Thromb Haemost.* 7 :982-91, 2009.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

84. Chandler, A.B., Earhart, A.D., Speich, H.S., Kueter T.J., Hansen, J., White, M.M., and **Jennings, L.K.** Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. *Thromb Res. Jan*; 125(1):44-52. Epub 2009 May 31, 2009.
85. Zhang, F., Kotha, J., Jennings, L.K., Zhang, X.A. Tetraspanins and vascular functions. *Cardiovasc Res. 83 (1): 7-15, 2009.*
86. Deibele, A.J., **Jennings, L.K.**, Tchong, J.E., Neva, C., and Gibson, C.M. Intracoronary eptifibatide bolus administration during percutaneous coronary intervention for acute coronary syndromes with evaluation for platelet GPIIb/IIIa receptor occupancy and platelet function, the ICE Trial, *Circulation (Intervention Circulation. Feb 16;121(6):784-91. Epub 2010 Feb 1, 2010.*
87. Bonello, L., Tantry, U.S., Marcucci, R., Blindt, R., Angiolillo, D.J., Becker, R., Bhatt, D.L., Cattaneo, M., Collet, J.P., Cuisset, T., Gachet, C., Montalescot, G., **Jennings, L.K.**, Kereiakes, D., Sibbing, D., Trenk, D., Van Werkum, J.W., Paganelli, F., Price, M.J., Waksman, R., Gurbel, P.A., for the working group on High on-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP, *J. Amer Coll Cardiol, 56: (12): 919-33, 2010.*
88. Pasquali, S.K., Yow, E., **Jennings, L. K.**, and Li, J.S. Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. *Congenit Heart Dis. 5 (6): 552-5, 2010.*
89. Jaslow, C.R., Patterson, K. S., Cholera, S., **Jennings, L.K.**, Ke, R.W., and Kutteh, W.H. CD9 expression by human granulose cells and platelets as a predictor of fertilization success during IVF. *Obstet Gynecol Int. pii 192461. E pub 2010.*
90. Becker, R.C., Gibson, M.C., **Jennings, L.K.**, and Morrow, D.A. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. *Am J Cardiol. Oct 15; 106(8): S2-3, 2010.*
91. Hudson, J.Q., McNeely, E.B., Green, C.A., and **Jennings, L.K.** Assessment of eptifibatide clearance by hemodialysis using an in vitro system. *Blood Purif. 30(4):266-71, 2010.*
92. Richardson, M.M., Jennings, L.K., Zhang, X.A. Tetraspanin and tumor progression. *Clin Exp Metastasis 28 (3):261-70, 2011.*
93. Kosoglou, T., Reyderman, L., Kasserra, C, **Jennings, L.K.**, Young, S., Xuan, F., Pei, J., Maxwell, S.E., Schiller, J., Meehan, A.G., and Cutler, D.L. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. *Eur J Clin Pharmacol 68:291-300, 2012.*
94. McCanless, J.D., **Jennings, L.K.**, Cole, J.A., Bumgardner, J.D., Haggard, W.O. In vitro differentiation and biocompatibility of mesenchymal stem cells on a novel platelet releasate-containing injectable composite. *J Biomed Mater Res A. 100: 220-9, 2012.*
95. Tricoci, P., Huang, Z., Held, C., Moliterno, D.J., Armstrong, P.W., Van de Werf, F., White, H.D., Aylward, P.E., Wallentin, L., Chen, E., Lokhnygina, Y., Pei, J., Leonardi, S., Rorick, T.L., Kilian, A.M., **Jennings, L.H.K.**, Ambrosio, G., Bode, C., Cequier, A., Cornel, J.H., Diaz, R., Erkan, A., Huber, K., Hudson M.P., Jiang, L., Jukema, J.W., Lewis, B.S., Lincoff, A.M., Montalescot, G., Nicolau, J.C., Ogawa, H., Pfisterer, M., Prieto, J.C., Ruzyllo, W., Sinnaeve, P.R., Storey, R.F., Valgimigli, M., Whellan, D.J., Widimsky, P., Strony, J., Harrington, R.A., Mahaffey, K.W.; the TRACER Investigators. Thrombin-receptor antagonist Vorapaxar in acute coronary syndromes. *NEJM Nov 13, Epub ahead of print, 2011.*
96. **Jennings, L.K.**, Michelson, A.D., Jacoski, M.V., Tyagi, A., Grgurevich, S. Li, J.S for the PICOLO Investigators. Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: A comparative study of platelet aggregation response. *Platelets Feb 6, 2012.*

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

97. Kosoglou, T., Kraft, W.K., Kumar, B., Statkevich, P., Xuan, F., Ma, L., **Jennings, L.K.**, Schiller, J.E., Langdon, R.B., and Cutler, D.L. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. *Eur J Clin Pharmacol*, Feb 8, 2012.
98. McCanless, J.D., **Jennings, L.K.**, Bumgardner, J.D., Cole, J.A., Haggard, W.O. Hematoma-inspired alginate/platelet releasate/CaPO<sub>4</sub> composite: initiation of the inflammatory-mediated response associated with fracture repair in vitro and ex vivo injection delivery. *J Mater Sci Mater Med* 23 (8):1971-81, 2012.
99. McCanless, J.D., **Jennings, L.K.**, Cole, J.A., Bumgardner, J.D., Haggard, W.O. Induction of the early inflammatory-mediated cellular responses of fracture healing in vitro using platelet releasate-containing alginate/CaPO<sub>4</sub> biomaterials for early osteoarthritis prevention. *J Biomed Mater Res A* 100; 1107-14, 2012.
100. Rowley, J.W., Finn, A.V., French, P.A., **Jennings, L.K.**, Bluestein, D., Gross, P.L., Freedman, J.E., Steinhubl, S.R., Zimmerman, G.A., Becker, R.C., Dauerman, H.L., Smyth, S.S. 2011 Platelet Colloquium Participants. Cardiovascular devices and platelet interactions; understanding the role of injury, flow, and cellular responses. *Cir Cardiovas Interven*,5: 296-304, 2012.
101. Angiolillo, D.J., Welsh, R.C., Trenk, D., Neumann, F.J., Conley, P.B., McClure, M.W., Stephens, G., Kochman, J., **Jennings, L.K.**, Gurbel, P.A., Wójcik, J., Dabrowski, M., Saucedo, J.F., Stumpf, J., Buerke, M., Broderick, S., Harrington, R.A., Rao, S.V. Pharmacokinetic and pharmacodynamic effects of elinogrel: Results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. *Circ Cardiovasc Interv.* 2012 Jun 1;5(3):347-56. Epub 2012 May 22.
102. Mills, R.M., Berkowitz, R.D., Damaraju, C.V., **Jennings, L.K.**, Wildgoose, P. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: The Safe, Simple Transitions (SST) study. *Thromb Res. Nov*; 130 (5):709-15, 2012.
103. Speich, H.E., Furman, R.R., Lands, L.L., Moodie, G.D., and **Jennings, L.K.** Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability. *J Thromb Thrombolysis*, 36:31-41, 2013.
104. Herr, M.J., Kotha, JP, Hagedorn, N., Smith, B., and **Jennings, L.K.** Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9, *PLOS One*, 8(6): e67766. doi:10.1371/journal.pone.0067766, 2013.
105. **Jennings, L.K.**, Kotha, J. The utility of platelet and coagulation testing of antithrombotics: Fusing science with patient care. *Drug Dev Res.* 2013 Dec;74(8):587-593. Epub 2013 Nov 15, 2013.
106. Herr, M.J., Mabry, S.E., Jameson, J.F., and **Jennings, L.K.** Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is regulated by epidermal growth factor receptor. *Biochem. Biophys. Res. Commun.* 442: 99-104, 2013.
107. Storey, R.F., Kotha, J. (co-first authors), Smyth, S., Moliterno, D.J., Rorick, T.L., Moccetti, T., Valgimigli, M., Dery, J.P., Cornel, J.H., Thomas, G.S., Huber, K., Harrington, R.A., Hord, E., Judge, H., Chen, E., Strony, J., Mahaffey, K.W., Tricoci, P., Becker, R.C., **Jennings, L.K.** Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes: the TRACER pharmacodynamic substudy. *Thromb. Haemost.* Jan 9:111(5), 2014.
108. Mahaffey, K.W., Huang, Z., Wallentin, L., Storey, R.F., **Jennings, L.K.**, Tricoci, P., White, H.D., Armstrong, P.W., Aylward, P.E., Moliterno, D.J., Van de Werf, F., Chen, E, Leonardi, S., Rorick, T., Held, C., Strony, J. ST-segment elevation acute coronary syndrome (from the TRACER Trial). *Am J Cardiol.* Mar 15;113(6):936-44,2014.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

109. Judge, H.M., **Jennings, L.K.**, Moliterno, D.J., Hord, E., Ecob, R., Tricoci, P., Rorick, T., Kotha, J., Storey, R.F..PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. *Platelets*. Apr 21, 2014.
110. Herr M.J., Longhurst C.M., Baker B., Homayouni R., Speich H.E., Kotha J., **Jennings L.K.** Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity. *Biochem Biophys Res Commun*. May 16;447(4):616-20, 2014.Epub 2014 Apr 18.
111. Speich, H.E., Bhal, V., Houser, K.H., Caughran, A.T., Lands, L.T., Houng, A.K., Bäckstrom, J., Enerbäck, M., Reed, G.L., **Jennings, L.K.** Signaling via P2Y12 may be critical for early stabilization of platelet aggregates. *J Cardiovasc Pharmacol*. Jun; 63(6):520-7, 2014.
112. Chen, J, Wang, J, Schwab, LP, Park, KT, Seagroves, TN, **Jennings, LK**, Miller, DD, Li, W. Benzimidazole Analogs as Potent Hypoxia Inducible Factor Inhibitors: Synthesis, Biological Evaluation, and Profiling Drug-like Properties. *Anticancer Res*. Aug;34(8):3891-904, 2014.
113. Herr, M.J., Mabry, S.E., **Jennings, L.K.** Tetraspanin CD9 regulates cell contraction and actin arrangement via RhoA in human vascular smooth muscle cells.. *PLoS One*. Sept 3;9(9),2014.
114. Tricoci, P., Lokhnygina, Y., Huang, Z., Van de Werf, F, Cornel, J.H., Chen, E., Wallentin, L., Held, C., Aylward, P.E., Moliterno, D.J., **Jennings, L.K.**, White, H.D., Armstrong, P.W., Harrington, R.A., Strony, J., Mahaffey, K.W. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. *Am Heart J*. Dec;168(6):869-877, 2014.
115. Chen, X., Huang, Y., Yang, G., Li, J., Wang, T., Schulz, O.H., **Jennings, L.K.** Polydopamine integrated nanomaterials and their biomedical applications. *Current Pharmaceutical Design*, Bentham Science Pub, *Curr Pharm Des*. Aug 31. [Epub ahead of print], 21(29): 4262-75, 2015.
116. Bhal, V., Herr, M.J., Dixon, M., Akins, S., Hord, E., White MM, Seiffert, D, Kotha, J, **Jennings, L.K.** Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model. *Thromb Res*. [Epub ahead of print] Sep 11, 2015.
117. Ramsey, M.T., Fabian, T.C., Shahan, C.P., Sharpe, J.P., Mabry, S.E., Weinberg, J.A., Croce, M.A., **Jennings, L.K.** A prospective study of platelet function in trauma patients. *J Trauma Acute Care Surg*. Feb 18, 2016.
118. Garner, J.M., Herr, M.J., Hodges, K.B., **Jennings, L.K.** The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma. *Biochem Biophys Res Commun*. Feb 26; 471(1):21-5, 2016.
119. Gibson, C.M., **Jennings, L.K.**, Chi, G., ...Cohen, A.T., Harrington, R.A. Association of D-dimer levels with clinical event rates and the efficacy of betrixaban versus enoxaparin in APEX trial. *TH Open*. 8;2 (1):e16-24, 2018.
120. Borst, O., Unzer, P., Alnaggar, N., Geue, S., Tegtmeyer, R., Rath, D., Droppa, M., Seizer, P., Heitmeier, S., Heemskerk, J.W.M., **Jennings, L.K.**, Storey, R.F., Angiolillo, D.J., Rocca, B., Spronk, H., Cate, H.T., Gawaz, M., and Geisler, T. Inhibitory mechanisms of very low dose rivaroxaban in non-ST-elevation myocardial infarction. *Blood Adv*. 2018 Mar 27;2(6):715-730. doi: 10.1182/bloodadvances. 2017013573.
121. Tricoci, P., Neely, M., Whitley, M.J., Edelstein, L.C., Simon, L.M., Shaw, C., Fortina, P., Moliterno, D.J., Armstrong, P.W., Aylward, P., White, H., Van de Werf, F., **Jennings, L.K.**, Wallentin, L., Held, C., Harrington, R.A., Mahaffey, K.W., and Bray, P.F. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. *Blood Cells Mol Dis*. 2018 Sep; 72:37-43. doi: 10.1016/j.bcmd.2018.07.004. Epub 2018 Jul 21.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

122. Bhatt, D.L., Pollack, C.V., Weitz, J.I., **Jennings, L.K.**, Xu, S., Arnold, S.E., Umstead, B.R., Mays, M.C., Lee, J.S. Antibody-based ticagrelor reversal agent in healthy volunteers. *N Engl J Med.* 2019 Mar 17. doi:10.1056/NEJMoa1901778. [Epub ahead of print], 380 (19):1825-1833.
123. Franchi, F., Rollini, F., Kairouz, V., Rivas, J., Rivas, A., Agarwal, M., Briceno, M., Wali, M., Nawaz, A., Silva, G., Shaikh, Z., Maaliki, N., Been, L., Piraino, J., Pineda, A.M., Suryadevara, S., Soffer, D., Zenni, M.M., **Jennings, L.K.**, Bass, T.J., Angiolillo, D.J. Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: the OPTIMUS-5 Study. *JACC: Basic to Translational Science*, 4: 763-775, 2019.
124. d'Alessandro, E., Becker, C., Bergmeier, W, ...**Jennings, L.K.**, ..., H ten Cate, H. Thrombo-inflammation in cardiovascular disease: An expert consensus document from the 3<sup>rd</sup> Maastricht Consensus Conference on Thrombosis. *Thromb Haemost* 120: 538-564, 2020.
125. Franchi, F., Rollini, F., Faz, G., ...**Jennings, L.K.**, Bass, T.A., Angiolillo, D.J. Pharmacodynamic effects of vorapaxar in prior myocardial infarction patients treated with potent oral P2Y12 receptor inhibitors with and without aspirin: Results of the VORA-PRATIC study. *J Am Heart Assoc* 21; 9(8): e015865, 2020.
126. Bhatt, D.L., Pollack, C.V., Mazer, C.D.,...**Jennings, L.K.**,...Verma, S., for the REVERSE-IT Investigators. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. *NEJM Evidence.* December 1, 2021; DOI:https://doi.org/10.1056/EVIDoa2100047.
127. Galli, M., Franchi, F., Rollini, F., ... **Jennings, L.K.**, Bass, T.A., and Angiolillo, D. Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel vs dual antiplatelet therapy in patients with atherosclerotic disease. *Thromb Haemost*, 122 (8): 1341-1351, 2022.
128. Galli M., Franchi, F., Rollini, F., ... **Jennings, L.K.**, Bass, T.A., Angiolillo, D.J. Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: A pharmacodynamic study of dual pathway inhibition versus dual antiplatelet therapy. *Eur Heart J Cardiovasc Pharmacother* 2022 Sept 29; 8 (7): 728-737, 2022.

**Chapters, Reviews and Books:**

1. Phillips, D.R., **Jennings, L.K.**, Berndt, M.C., Prasanna, H.R., Fox, J.E.B., and Edwards, H.H. Platelet membrane glycoproteins as thrombin and aggregation receptors. In, Roman, A., Meyer, F.A., Gitler, G., and Silberberg, A. (eds.), Platelets: Cellular Response Mechanisms and Their Biological Significance. John Wiley & Sons, Ltd., pp. 131-141, 1980.
2. Phillips, D.R., **Jennings, L.K.**, and Berndt, M.C. Studies of inherited bleeding disorders to identify platelet membrane glycoproteins involved in adhesion and aggregation. Membranes and Genetic Disease, Alan R. Liss, Inc., pp. 151-163, 1982.
3. **Jennings, L.K.**, and Jackson, C.W. Heterogeneity of fibrinogen receptor expression on human platelets activated by ADP in native plasma in: Jamieson, G.A., (ed) Platelet Membrane Receptors: Molecular Biology, Immunology, Biochemistry and Pathology. Alan R. Liss, Inc., pp. 381-385, 1988.
4. Longhurst C.M., and **Jennings, L.K.** Signal transduction, the intracellular consequences of integrin activity. Cellular and Molecular Life Sciences, 54 (6) 514-526, 1998.
5. White, M.M., and **Jennings, L.K.** Platelet Protocols: Research and Clinical Laboratory Procedures, Academic Press, Inc., 1999.
6. **Jennings, L.K.**, Crossno, Jr., J.T., and White, M.M. CD9 Structure and Function: Berndt, M.C., (ed) Platelets, Thrombosis and the Vessel Wall, Advances in Vascular Biology, Gordon and Breach, Inc.; 173-188, 2000.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

7. **Jennings, L.K.** Clinical Trials of the Parenteral Glycoprotein IIb-IIIa Inhibitors: The influence of Dose Selection on Results, A CME Booklet, Health Science Communications, 2001.
8. Lu, Y. Beheshti B., Zhang, J, Squire J.A., Yang, X.J., Bhattacharya S.K., and **Jennings, L.K.** Characterization of a novel apoptosis-inducing gene in prostate cancer. Progress in Prostate Cancer Research. (Ed.) Columbus, F. Nova Science Publishers, Inc.: Hauppauge, NY. 2004.
9. **Jennings, L.K.** in Platelet Function: Assessment, Diagnosis, and Treatment, ed. Quinn and Fitzgerald, Humana Press, 2005.
10. **Jennings, L.K.** Current Strategies With Eptifibatid and Other Antiplatelet Agents in Percutaneous Coronary Intervention and Acute Coronary Syndromes. Expert Opinion on Drug Metabolism & Toxicology (invited review), Vol. 1, No. 4, Pages 727-737, 2005.
11. **Jennings, L.K.** and White, M.M. Platelet Aggregation in Platelets, 2<sup>nd</sup> Edition, ed. Alan Michelson, Academic Press, 2006.
12. Saucedo, J. and **Jennings, L.K.** Antiplatelet and coagulant agents: Key differences in mechanisms of action, clinical application, and therapeutic benefit. *Curr Opin Cardiol* 23:2008.
13. **Jennings, L.K.** Variability in platelet response to the antiplatelet agents, aspirin and clopidogrel: Mechanisms, measurement and clinical relevance. *Crit Path Card*. 8:20-28, 2009.
14. Zhang,F., Kotha, J., **Jennings, L.K.**, and Zhang, X.A. Tetraspanins and Vascular Functions. *Cardiovasc. Res.* Feb 27, [Epub Ahead of Print] 2009.
15. **Jennings, L.K.** Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. *Thromb Haemost* 102: 248-57, 2009.
16. Richardson, M.M., **Jennings, L.K.**, and Zhang, XA. Tetraspanins and tumor progression. *Clin Exp Metastasis*. 28 (3): 261-70, 2011.
17. Giri,S. and **Jennings, L.K.** The spectrum of thrombin in acute coronary syndrome. *Thromb Res*. 135 (5):782-787, 2015.
18. **Jennings, L.K.**, Angiolillo, D., Levy, J., and Schneider, D.J. The role of platelet function testing in improving clinical outcomes. *Med Roundtable Cardiovasc.* Ed. May 14, 2018. Roundtable ID: CV43571.

**Abstracts:**

1. **Jennings, L.K.**, and Warren, C.O. Wall-softening during development in Chlamydomonas eugametos. *Botanical Soc of America, Pub.* 156: B58, 1978.
2. **Jennings, L.K.**, and Phillips, D.R. Rapid actin polymerization following thrombin activation of human platelets. *Fed Proc* 39: 2047, 1980.
3. **Jennings, L.K.**, and Phillips, D.R. Isolation of the aggregation site from human platelet membranes. *J Cell Biol* 87: ME202A, 1980.
4. **Jennings, L.K.**, and Phillips, D.R. Purification of membrane glycoproteins that mediate the interaction of human platelets. *J Supramol Struct Cell Biochem Suppl.* 5: 279, 1981.
5. Phillips, D.R., Berndt, M.C., **Jennings, L.K.**, and Fox, J.E.B. Platelet membrane glycoproteins: Role in aggregation. *J Supramol Struct Cell Biochem Suppl* 5: 344, 1981.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

6. Dockter, M.E., Brown, L.K., and **Jennings, L.K.** Quantitative determination at the single cell level of Protein 3 content in human erythrocytes. *Blood* 62: 31a, 1983.
7. **Jennings, L.K.**, Phillips, D.R., and Walker, W.S. Monoclonal antibodies to human platelet membrane glycoprotein IIb<sub>β</sub> that initiate distinct platelet responses. *Blood* 62: 258a, 1983.
8. **Jennings, L.K.**, Dockter, M.E., and Walker, W.S. Cytofluorimetric analysis of platelet membrane glycoproteins IIb and III using monoclonal antibodies. *Fed Proc* 43: 2085, 1984.
9. **Jennings, L.K.**, Wang, W., Ashmun, R.A., White, G.C., II, and Dockter, M.E. Rapid diagnosis and classification of Glanzmann's thrombasthenia by flow cytofluorimetry. *Thromb Haemost* 54: 19, 1985.
10. **Jennings, L.K.**, Ashmun, R.A., Phillips, D.R., Fitzgerald, L.A., and Dockter, M.E. Binding of human platelets to circulating blood monocytes occurs after venipuncture and is inhibited by prostacyclin. *Thromb Haemost* 54: 232, 1985.
11. Fitzgerald, L.A., Chediak, J., **Jennings, L.K.**, Strother, S.V. and Phillips, D.R. Identification of molecular variants of Glanzmann's thrombasthenia. *Blood* 66: 289a, 1985.
12. **Jennings, L.K.**, Wang, W.C., and Jackson, C.W. Assessment of the function of transfused platelets in a patient with Glanzmann's thrombasthenia. *Blood* 68: 309a, 1986.
13. Jackson, C.W., Ashmun, R.A., and **Jennings, L.K.** Flow cytometric examination of fibrinogen binding to platelets activated in native plasma. *Blood* 68: 318a, 1986.
14. Peiper, S.C., Look, A.T., **Jennings, L.K.**, Berard, C.W., and Sherr, C.J. The p24 antigen recognized by CD9 monoclonal antibodies is related to the subunit of the cytoadhesion receptor: Biochemical comparison and DNA-mediated gene transfer. Third International Conference on Malignant Lymphoma, 1986.
15. **Jennings, L.K.**, Dockter, M.E., Wall, C.D., and Fox, C.F. Measurement of calcium mobilization in human platelets using indo-1 and flow cytometry. *Blood* 70: 352a, 1987.
16. **Jennings, L.K.**, and Fox, C.F. Purification and partial characterization of a glycoprotein associated with monoclonal antibody-induced activation of human platelets. *Blood* 70: 352a, 1987.
17. **Jennings, L.K.**, Wall, C.D., Fox, C.F., Zhao, J., and Mauer, A.M. Altered expression of cell surface receptors for extracellular matrix glycoproteins in promyelocytic cell lines HL60 and KG-1a. *Proceedings of the American Association of Cancer Research* 29: 133, 1988.
18. Kouns, W.C., Fox, C.F., and **Jennings, L.K.** Perturbation of GPIIIa induces the exposure of fibrinogen binding sites. *Circulation* 78(4): II-622, 1988.
19. **Jennings, L.K.**, Fox, C.F., Dockter, M.E., and Wall, C.D. Calcium mobilization in normal and Glanzmann's thrombasthenic platelets. *Circulation* 78: (4) II-517, 1988.
20. **Jennings, L.K.**, Wall, C.D., Fox, C.F., Dockter, M.E., Zhao, J., and Mauer, A.M. The expression of platelet GP IIb-IIIa on myelocytic cell lines - a possible differentiation marker for myeloid cells. *Blood* 72 (5): 326a, 1988.
21. **Jennings, L.K.**, Chesney, C.M., and Fox, C.F. A platelet aggregation defect suggesting interaction of p24/CD9 with GPIIb. *Blood* 72 (5): 325a, 1988.
22. **Jennings, L.K.**, Fox, C.F., Kouns, W.C., McKay, C.P., and Schultz, H.E. The activation of human platelets mediated by anti-platelet p24/CD9 monoclonal antibodies. *Blood* 72 (5): 325a, 1988.
23. Kouns, W.C., Fox, C.F., Lamoreaux, W.J., Coons, L.B., and **Jennings, L.K.** The effects of GPIIb-IIIa receptor occupancy on platelet cytoskeletal organization. *Blood* 74(17): 341a, 1989.



**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

24. Kouns, W.C., Fox, C.F., Lamoreaux, W.J., Coons, L.B., and **Jennings, L.K.** Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor. *Blood* 74(17): 336a, 1989.
25. **Jennings, L.K.**, Kouns, W.C., and Fox, C.F. A topographical relationship between platelet membrane GPIb and the Fc receptor, Fc $\gamma$ RII. *Blood* 74(17): 633a, 1989.
26. **Jennings, L.K.**, Fox, C.F., and Kouns, W.C. Platelet activation mediated by the surface protein p24/CD9. *Blood* 74(17): 1091a, 1989.
27. Kouns, W.C., Rubinstein, E., Carroll, R.C., White, M.M., and **Jennings, L.K.** Induction of antibody-Fc $\gamma$ RII-mediated activation through alteration of the cytoskeleton. *Circulation* 82(4): III-131, 1990.
28. Lanza, F., Wolf, D., Fox, C.F., Fried, V.A., Phillips, D.R., and **Jennings, L.K.** cDNA cloning of the platelet membrane p24/CD9: Evidence for a new family of multiple membrane spanning proteins. *Circulation* 82 (4): III-596, 1990.
29. **Jennings, L.K.**, Fox, C.F., Kouns, W.C., Williams, M.A., and Seyer, J.M. Properties of p24/CD9. *Circulation* 82 (4): III-663, 1990.
30. Wall, C.D., Fox, C.F., Hermann-Petrin, J., Dockter, M.E., and **Jennings, L.K.** The expression of platelet glycoprotein IIb-IIIa on myeloid leukemic cell lines. *Blood* 76(10): 1911a, 1990.
31. Crossno, J.T., Jr., Fox, C.F., Dockter, M.E., and **Jennings, L.K.** The p24/CD9 antigen in pre-B cell lines and platelets: Unique properties of a new family of multiple membrane spanning proteins. *Blood* 76(10): 1804a, 1990.
32. Kouns, W.C., Puckett, K.J., Miller, A.A., Fox, C.F., and **Jennings, L.K.** Partial mapping of functionally significant GPIIIa epitopes. *Blood* 76 (10), 1845a; 1990.
33. Cook, G.A., Slack, S.M., **Jennings, L.K.**, Wang, W.C., and Turitto, V.T. RBC adhesion to endothelial cells in pediatric subjects with sickle cell disease: effect of crisis. *Annals of Biomed Engineering* 22: 26, 1990.
34. Heath, T.L., Slack, S.M., White, M.M., Kouns, W.C., Robertson, J.T., Steiner, B., Turitto, V.T., and **Jennings, L.K.** Thrombin hydrolysis of human GPIIb-IIIa upon complex activation. *Blood* 78 (10): 138a, 1991.
35. Steiner, B., Kouns, W.C., Jennings, L.K, and Hadvary, P. Inhibitor-induced conformational changes in platelet GPIIb-IIIa are reversible on intact platelets but irreversible in solution. *Blood* 78 (10): 393a, 1991.
36. Wall, C.D., Studtmann, K., Hermann-Petrin, J., Dockter, M.E., and **Jennings, L.K.** The GPIIIa MAb D3 induces a conformational change in the GPIIb-IIIa complex that binds both soluble and immobilized fibrinogen on human erythroleukemia cells. *J Cell Biochem* 16F: 180, 1992.
37. Heath, T.L., Wall, C.D., Turitto, V.T., and **Jennings, L.K.** Ligand specificity of a GPIIIa LIBS. *Blood* 80(10): 128a, 1992.
38. Kouns, W.C., Weller, T., Hadvary, P., and **Jennings, L.K.** Identification of a peptidomimetic inhibitor with minimal effects on the conformation of GPIIb-IIIa. *Blood* 80(10): 165a, 1992.
39. Slack, S.M., **Jennings, L.K.**, and Turitto V.T. Shear-induced changes in platelet adhesion to immobilized human fibrinogen. *Cardiovascular Science and Technology Conference*, Bethesda, MD, 1992.
40. Wall, C.D., Kiick, D.M., and **Jennings, L.K.** Evidence for multiple conformations of GPIIb-IIIa which display varying ligand competency on resting platelets. *Blood* 80(10): 128a, 1992.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

41. **Jennings, L.K.**, and White, M.M. Utilization of the anti-LIBS D3 in animal models for thrombosis and hemostasis. *Thromb Haemost* 69 (6): 591, 1993.
42. Kouns, W.C., Jutzi, J., **Jennings, L.K.**, and Steiner, B. Disulfide reduction "activates" integrin  $\alpha_{IIb}\beta_3$  (GPIIb-IIIa). *Thromb Haemost* 69 (6): 785, 1993.
43. Brisson, C., **Jennings, L.K.**, Cazenave, J.P., and Lanza, F. CD9 is in platelet  $\alpha$ -granules and co-localizes with GPIIb-IIIa in contact zones and pseudopodia of activated platelets. *Thromb Haemost* 69 (6): 925, 1993.
44. Slack, S.M., Wall, C.D., Turitto, V.T and **Jennings, L.K.** A monoclonal antibody to platelet glycoprotein (GP) IIb that exhibits reduced activity to the peptide-occupied GPIIb-IIIa receptor. *Thromb Haemost* 69(6), 1993.
45. Slack, S.M., **Jennings, L.K.**, and Turitto, V.T. Evaluation of shear stress-induced platelet aggregation from platelet size distribution measurements. *Thromb Haemost* 69(6): 995, 1993.
46. Delanty, N., **Jennings, L.K.**, Moran, N., Catella, F., FitzGerald, G.A., and Fitzgerald, D.J. Antagonism of the platelet glycoprotein IIb-IIIa receptor in stable angina: Effects on platelet activity and receptor conformation. *Circulation* Oct; 88 (4 Pt 2): I1-827, 1993.
47. Wall, C.D., White, M.M., and **Jennings, L.K.** Activation of GP IIb-IIIa in HEL cells. *Blood* 82(10): 210a, 1993.
48. Wall, C.D., and **Jennings, L.K.** Comparisons of conformations of GPIIb-IIIa in platelets and HEL cells using monoclonal antibodies. *Blood* 82(10): 75a, 1993.
49. Heath, T.L., Wall, C.D., and **Jennings, L.K.** Alterations of high and low affinity conformations of GPIIb-IIIa as a result of ligand-receptor interaction. *Blood* 82(10): 75a, 1993.
50. **Jennings, L.K.**, Fitzgerald, D., and White, M.M. An active conformation of platelet GPIIb-IIIa that binds to fibrin(ogen) does not mediate clot retraction. *Blood* 82(10): 211a, 1993.
51. Wilkinson, D.A., Mattson, J.C., Crossno, J.T., Jr., and **Jennings, L.K.** p24/CD9: Localization at platelet and CHO cell-cell contacts and potential role in proliferation. *FASEB Journal* 8: 1406a, 1994.
52. **Jennings, L.K.**, White, M.M., and Spiers, K.D. Receptor occupancy of GPIIb-IIIa by Integrelin correlates with inhibition of platelet aggregation. *Blood* 84(10): 72a, 1994.
53. Cook, G.A., Wang, W.C., Dancy, R.M., Slack, S.M., **Jennings, L.K.**, and Turitto, V.T. Increased RBC adhesion to endothelial cells in children with sickle cell disease during pain crisis. *Blood* 84(10): 408a, 1994.
54. **Jennings, L.K.**, Orthofer, C.S., and Wilkinson, D.A. Platelet CD9 binds the adhesive protein fibronectin. *Blood* 84(10): 471a, 1994.
55. Beaty, O., III, Wang, W.C., White, M.M., **Jennings, L.K.**, Chesney, C.M., Stenberg, P.E., Bhakta, M., and Jackson, C.W. A new giant platelet syndrome with mild bleeding despite increased platelet reactivity. *Blood* 84(10): 475a, 1994.
56. Crossno, J.T., Jr., Mattson, J.C., and **Jennings, L.K.** CD9 as a recognition molecule in cell-cell contacts. *Circulation* 90: 2136, 1994.
57. Wilkinson, D.A., Fitzgerald, T.J., and **Jennings, L.K.** The newly discovered adhesion molecule CD9 binds fibronectin and integrin  $\alpha_{IIb}\beta_3$ . *FASEB*: 9 (6) A1500, 1995.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

58. Crossno, J.T., Jr., White, M.M., Wilkinson, D.A., **Jennings, L.K.** The tetraspanin CD9 is a Cell Adhesion Molecule. *FASEB*: 9 (6) A1377, 1995.
59. Crossno, J.T., Jr., Poppleton, H.M., White, M.M., Wilkinson, D.A., Patterson, K.S., Raghov, R., and **Jennings, L.K.** The large extracellular loop of p24/CD9 contributes to cell motility and spreading on fibronectin. *Blood* 86: 282a, 1995.
60. **Jennings, L.K.**, Wilkinson, D.A., and Crossno, J.T., Jr. CD9 is a cell adhesion molecule on human platelets. *Blood* 86: 282a, 1995.
61. **Jennings, L.K.**, White, M.M., and Slack, S.M. Signaling mechanisms associated with crosslinking of platelet receptors. *Blood* 86: 552a, 1995.
62. Slack, S.M., and **Jennings, L.K.** Physiologic and pathophysiologic shear stress induces tyrosine phosphorylation of multiple platelet proteins. *Blood* 86: 84a, 1995.
63. White, F.L., Bryson, D.S., White, M.M., and **Jennings, L.K.** A myelodysplastic syndrome presenting as an acquired Glanzmann-like platelet defect. *Blood* 86: 805a, 1995.
64. Murphy N., **Jennings, L. K.**, Practico, D., Doyle, C., and Fitzgerald, D. Functional relevance of LIBS expression in the response to platelet glycoprotein IIb/IIIa antagonists in vivo. *Thromb Haemost* 73: 1314, 1995.
65. Jackson, D.E., **Jennings, L.K.**, and Newman, P.J. A mutation within the ligand binding domain of glycoprotein (GP) IIIa (integrin  $\alpha$ 3) results in an unstable GPIIb-IIIa complex that retains partial function in a novel form of Glanzmann's thrombasthenia. *Blood* 88(10): 280a, 1996.
66. **Jennings, L.K.**, Crossno, J.T., and White, M.M. Further characterization of the adhesive properties of CD9 and identification of CD9-fibronectin contact sites. *Blood* 88 (10): 624a, 1996.
67. **Jennings, L.K.**, White, M.M., Longhurst, C.M., Cook, G.A., and Mendoza, M.C. Monitoring GPIIb-IIIa antagonist receptor blockade. *Thromb Haemost* 78 (6): 1530, 1997.
68. Tchong, J.E., Thel, M.C., **Jennings, L.K.**, Joseph, D., Card, T.L., Talley, J.D., Kleinman, N.S., Gilchrist, I.C., Lorenz, T.J., and Kitt, M.M. Platelet glycoprotein IIb/IIIa receptor blockade with high dose Integrilin in coronary intervention. Results of the PRIDE study. *European Society of Cardiology, Stockholm, August, 1997.*
69. Cook, G.A., Wilkinson, D., Crossno, J.T., and **Jennings, L.K.** Surface Expression of CD9 influences the adhesion and spreading of chinese hamster ovary cells on immobilized fibronectin. *Mol Biol Cell Suppl*: 2306A, 1997.
70. Longhurst, C.M., Wilkinson, D., White, M.M., and **Jennings, L.K.** Characterization of a noncovalent association between CD9, GPIIb-IIIa and integrin associated protein (IAP50) on the surface of human platelets. *Mol Biol Cell Suppl*: 1679A, 1997.
71. **Jennings, L.K.** , Wise, R., Ramsey, K., Jacoski, M., Tamby, J.F., May, S., White, M., Cholera, S., Mendoza, C., Todd, M., Rush, J., and Giugliano, R. Comparison of platelet aggregation response and receptor occupancy of RPR 109891 administered intravenously in patients with recent acute coronary syndromes. *J American College of Cardiology* 31 (2) Supplement A, 93A, 1998.
72. **Jennings, L.K.** , Tardiff, B., Kitt, M., Gretler, D. Comparison of receptor occupancy and platelet aggregation response of eptifibatide administered intravenously in patients with unstable angina or non-Q wave myocardial infarction. *J American College of Cardiology* 31 (2) Supplement A, 353A, 1998.
73. Slack, S.M., **Jennings, L.K.** Characterization of platelet glycoprotein IIb-IIIa binding to polymeric material. *Biomedical Engineering Society*, Oct., 1998.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

74. **Jennings, L.K.**, White, M.M., Mendoza, M.C., Cholera, S., Slack, S.M. Comparison of pharmacodynamic effects of GPIIb-IIIa receptor blockades. *Circulation* 98 (17) I-1887, 1998.
75. **Jennings, L.K.**, Berkowitz, S.D., Ramsey, K.E., Zidar, J.P. Evaluation of the safety and pharmacodynamic effect of an oral GPIIb-IIIa antagonist, Klerval™ (RPR 109891) versus ticlopidine. *Circulation* 98 (17) I2968, 1998.
76. Thel, M.C., Joseph, D., Zimmerman, H.E., **Jennings, L.K.**, Kleiman, N.S., Kereiakes, D.J., Talley, D.J., O'Brien, M.A., Lorenz, T.J., Tchong, J.E. Enhanced platelet IIb-IIIa Inhibition with eptifibatide via high-dose, double bolus dosing: Final results of the PRIDE Study. *Circulation* 98 (17) I-4431, 1998.
77. **Jennings, L.K.** The tetraspanin CD9 is important in the regulation of adhesion of CHO cells to fibronectin. National Heart, Lung, and Blood Institute of the National Institutes of Health 50<sup>th</sup> Anniversary, 1998.
78. Bao, J.X. and **Jennings, L.K.** Tetraspanin CD9 contains an extracellular epitope associated with increased cell proliferation. *Blood* 92 (10) 350a, 1998.
79. Longhurst, C.M., White, M.M., and **Jennings, L.K.** A complex including CD9,  $\alpha$ IIb $\beta$ 3, IAP, and GPIb/IX/V on human platelets is independent of platelet activation and receptor occupancy. *Blood* 92 (10) 71b, 1998.
80. Longhurst, C.M., Cook, G.A., Bao, J. CD9, A major surface protein, facilitates cell movement and spreading and is complexed with GPIIb-IIIa. *Thromb Haemost* 82 (8): 2251, 1999.
81. Berkowitz, S.D., Daly, R., and **Jennings, L.K.** Determination of dose response with Roxifiban versus aspirin in patients with coronary artery disease (CAD). *Thromb Haemost* 82 (8): 1238, 1999.
82. **Jennings, L.K.**, Giugliano, R.P., Jacoski, M.V., Rumor, T., Walsh, M.L., May, S., and Jensen, B.K. Pharmacodynamic evaluation of combined intravenous and oral GPIIb-IIIa antagonist administered in patients with acute coronary syndromes. *Thromb Haemost* 82 (8): 664, 1999.
83. Haga, J.H., Slack, S.M., and **Jennings, L.K.** Characterization of anti-platelet antagonist interaction with purified glycoprotein IIb-IIIa (GPIIb-IIIa). *Thromb Haemost* 82 (8): 496, 1999.
84. Madan, M., Berkowitz, S.D., Christie, D.J., **Jennings, L.K.**, Smit, A.C., Sigmoan, K.N., and Glazer, S., Tchong, J.E. Rapid assessment of GPIIb/IIIa blockade: An evaluation of PFA-100® as a point-of-care- technology during percutaneous coronary interventions (PCI)-Checkpoint Study. *Thromb Haemost* 82 (8): 1138, 1999.
85. **Jennings, L.K.**, Talley, J.D., Gilchrist, I.C., Tamby, J.F., Mackrell, K.J., Zidar, J.P., and Berkowitz, S.D. Pharmacodynamic evaluation of Klerval versus Ticlopidine after coronary stent revascularization *Thromb Haemost* 82 (8): 2292, 1999.
86. Mondoro, T.H., White, M.M., **Jennings, L.K.** Active GPIIb-IIIa Conformations that link ligand interaction with cytoskeletal reorganization. Oral presentation. First Conf. on Arteriosclerosis, Thrombosis and Vascular Biology AHA May 20-22, 2000. Accepted for the conference as an oral presentation.
87. **Jennings, L.K.**, White, M.M., Sullivan, C.D. Evaluation of GPIIb-IIIa antagonists and their contribution to platelet activation states. IXth International Vascular Biology, 2000. *J Submicroscopic Cytology and Pathology*, 23(3): B061, 2000.
88. Miller, D.D., Sardar, V.M., Elrod, D., Sun, G., Huiping, X., Dalton, J.T., Tigyi, G.T., Baker, D., Virag, T., Nusser, N., Fischer, D., Lörincz, Z., **Jennings, L.K.**, Bao, J., Parrill, A.L., Bautista, D., Liliom, K. Search for selective lysophosphatidic acid (LPA) antagonists.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

89. Haga, J., **Jennings, L.K.**, Slack, S.M. Shear Induced tyrosine phosphorylation ppsyk in human platelets. *Ann. Biomedical Eng.*, 28, supplement 1, S-78, 2000.
90. **Jennings, L.K.**, Cook, G.A., Longhurst, C.M., White, M.M., Grgurevich, S. Identification of a functional domain on CD9, a major platelet surface protein that affects cell adhesion processes and mAb mediated platelet activation. XVIII Congress of the International Society on Thrombosis and Haemostasis, 2001.
91. Haga, J.H., Slack, S.M., **Jennings, L.K.** Characterization of platelet microparticle formation and procoagulant activity in the presence of  $\alpha_{IIb}\beta_3$  antagonists under shear stress. XVIIIth Congress of the International Society of Thrombosis and Haemostasis, 2001.
92. Haga, J.H., **Jennings, L.K.**, Slack, S.M. Inhibition of aggregation and phosphotyrosine signaling by  $\alpha_{IIb}\beta_3$  antagonists in platelets under shear stress. XVIIIth Congress of the International Society of Thrombosis and Haemostasis, 2001.
93. Cook, G.A., Longhurst, C.M., Grgurevich, S., Crossno, Jr., J.T., and **Jennings, L.K.** Identification of a key extracellular domain important in CD9 regulation of CHO cell adhesion to fibronectin. *Mol. Biol. Cell*, Supplement, 2001.
94. Grgurevich, S. and **Jennings, L.K.** In vitro cholesterol depletion diminishes aggregations of human platelets. *Blood*, 2001.
95. Zhang, C., Jacobs, J.D., and **Jennings, L.K.** Interaction of MPO with vascular NAD(P)H oxidases derived ROS In the vascular wall and its role in vascular disease. *Circulation* 106 (19):II36, 2002.
96. Grgurevich, S., Krishnan, R., White, M.M., and **Jennings, L.K.** The effects of in vitro cholesterol lowering on collagen induced platelet secretion. 9<sup>th</sup> Midwest Platelet Conference, St. Louis, MO, 2002.
97. Lui, Henry K., Saucedo, J. F., Garza, L., Matin, Z., Guerra, G. J., Jacoski, M. V., **Jennings, L.K.** Comparative pharmacodynamic evaluation of eptifibatid and abciximab in patients with non-ST-segment elevation acute coronary syndromes: The TAM2 Study. *Am. College of Cardiol.*, March 2003.
98. Lu, Y., and **Jennings, L.K.** Characterization of a novel apoptosis-inducing gene and its application in prostate cancer gene therapy. *American Society of Gene Therapy*, June, 2003.
99. He, B., Liu, L., Cook, G.A., Grgurevich, S., **Jennings, L.K.**, and Zhang, X.A. Tetraspanin KAI1/CD82 attenuates cellular morphogenesis through down-regulating integrin  $\alpha_6$ -mediated cell adhesion. *University of Tennessee Cancer Institute (UTCI) Research Day*, Nov, 2003.
100. White, M.M., Krishnan, R., Jacoski, M.V., and **Jennings, L.K.** Evaluation of the Point of Care Helena ICHOR/Plateletworks<sup>®</sup> and the Accumetrics Ultegra<sup>®</sup> RPFA for Assessment of Platelet Function with Small Molecule GPIIb-IIIa Antagonists, *J. Thromb and Haemostasis, Suppl.*, 2003.
101. Kotha, J., Longhurst, C.M., Pfeffer, S., Pfeffer, L., Grgurevich, S., Cook, G.A., Rao, G.N., and **Jennings, L.K.** Phosphatidylinositol 3-kinase regulates CD9-mediated haptotactic motility to fibronectin. *Mol. Biol. Cell (Suppl)* 14: 2003.
102. Grgurevich, S., Krishnan, R., and **Jennings, L.K.** Conventional PKCs/PKCmu are involved in mediating GPIIb-IIIa dependent outside-in signaling. 10<sup>th</sup> Midwest Platelet Conference, Milwaukee, 2004.
103. Speich, H.E., Slack, S.M., and **Jennings, L.K.** Increased phosphorylation of the tyrosine kinase syk in platelets exposed to pathophysiological levels of wall shear stress. 10<sup>th</sup> Midwest Platelet Conference, Milwaukee, 2004.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

104. Freidenstein, J., Jennings, L.H., Cholera, S., and **Jennings, L.K.** CD9 contributes to platelet adhesion to fibronectin and may be modulated by GPIIb-IIIa activation states. 10<sup>th</sup> Midwest Platelet Conference, Milwaukee, 2004.
105. White, M.M., Krishnan, R., Kueter, T.J., Jacoski, M.V., and **Jennings, L.K.** Point of care systems to monitor platelet function. 10<sup>th</sup> Midwest Platelet Conference, Milwaukee, 2004.
106. Chandler, B., Kueter, T.J., Hansen, J., and **Jennings, L.K.** Regulation of CD154 (CD40L) and CD62 (p-selectin) cell surface density may be a critical mechanism in conferring proinflammatory and prothrombotic effects. *J. Thromb and Haemostasis* Vol 3, Supp. 1: P1013, 2005.
107. Speich, H.E., S. Grgurevich, T.J. Kueter, S. M. Slack, and **Jennings, L.K.** Syk is phosphorylated at Y352 in response to shear stress and is critical for thrombus formation on Type III collagen under flow. 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, April 27-29, 2006.
108. Zhang, C., Kotha, J., Lu, Y., Longhurst, C., Jacobs, J., Chang, Y., Hassid, A., and **Jennings, L.K.** Tetraspanin CD9 regulates vascular smooth muscle cell migration and proliferation in vitro and neointima formation in vivo. 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, April 27-29, 2006.
109. Speich H. E., Grgurevich, S., Kueter, T.J., Slack S.M., and **Jennings, L.K.** Platelets Undergo Phosphorylation of Syk at Y525/526 and Y352 in Response to Pathophysiological Shear Stress. Presented at the 11th Biennial Midwest Platelet Conference, Chicago, Illinois, 2006.
110. White, M.M., Kueter, T.J., Hill, S. N., Speich, H.E., Earhart, A.D., and **Jennings, L.K.** GPIIb-IIIa antagonists induce platelet disaggregation and dissociate platelet thrombin in vitro. Presented at the 11th Biennial Midwest Platelet Conference, Chicago, Illinois, 2006.
111. Hill, S.N., Grgurevich, S., Cholera, S., Kotha, J., and **Jennings, L.K.** Matrix dependent effects on CD9 and GPIIb-IIIa localization: Insight into function. Presented at the 11th Biennial Midwest Platelet Conference, Chicago, Illinois, 2006.
112. Deibele, A.J., **Jennings, L.K.**, Kirtane, A.J., Pinto, D.S., Slovur, D.P., Lucca, M.J., Neva, C., Tchong, J.T., Gibson, C.M. Local platelet glycoprotein IIb/IIIa receptor occupancy with intracoronary eptifibatide during stenting, the ICE pilot trial. TCT 2006. Supplement, *Amer. J. Card.* 98(8),45M, 2006.
113. Li, J.S., Berezny, K.Y., Yow, E., Bokesh, P., Takahashi, M., Graham, Jr., T.P., Sanders, S.P., **Jennings, L.K.** for the PICOLO Investigators. Optimal dose of clopidogrel for platelet inhibition in children: Primary results of the PICOLO Trial, AHA, Nov. 2006, *Circulation*, 2006.
114. Jaslow, C.R., Kutteh, W.H., Ke, R.W., Patterson, K.S., Cholera, S., and **Jennings, L.K.** Relationship of the CD9 protein on human granulosa cells and platelets with fertilization rates in women undergoing in vitro fertilization (IVF), 62nd Annual Meeting of the American Society for Reproductive Medicine in New Orleans, Oct. 21-25, 2006.
115. Speich, H.E., Grgurevich, S., Kueter, T.J., Slack, S.M., **Jennings, L.K.** Tyrosine kinase Syk plays a pivotal role in platelet signaling initiated by pathophysiological shear stress. *Thromb. Haemost.* 5 Supplement 2:P-W-247, 2007.
116. Hudson, J.Q., Green, C.A., Beach, E.A., and **Jennings, L.K.** Estimation of eptifibatide clearance by dialysis using an in vitro system, National Kidney Foundation (NKF) 2008 Spring Clinical Meetings, April 2-6, 2008.
117. Longhurst, C.M., Kotha, J., Baker, B., Homayouni, R., and **Jennings, L.K.** CD9 augments FN modulated phenotypic switch of vascular smooth muscle cells. FASEB Summer Research Conference, June 2008.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

118. Kotha, J., Longhurst, C., Appling, W., **Jennings, L.K.** Molecular Mechanism of tetraspanin CD9 mediated cell motility. FASEB Summer Research Conference, June 2008.
119. **Jennings, L.K.**, Kotha, J., Longhurst, C.M., and Zhang, C. Tetraspanin CD9 is a novel target for the prevention of neointimal hyperplasia. FASEB Summer Research Conference, June 2008.
120. Speich, H., Caughran, J.D., Lands, L.T., and **Jennings, L.K.** Dispersal of preformed aggregates by the reversible P2Y12 antagonist cangrelor. Midwest Platelet Conference, Lexington, KY, 2008.
121. Kotha, J., Hill, S.N., and **Jennings, L.K.** Tetraspanin CD9 localizes to platelet-platelet contact regions and regulates platelet aggregation and thrombus stability. Midwest Platelet Conference, Lexington, KY, 2008.
122. Speich, H.E., **Jennings, L.K.** Syk as a Selective Target to Reduce Shear-induced Platelet Thrombosis. Oral Presentation, AHA, New Orleans, 2008.
123. Speich H.E., Earhart, A.D., Hill, S.N., Kueter T.J., White M.M., and **Jennings, L.K.** Platelet aggregation reversal by GPIIb-IIIa antagonists: Dependence upon agonist and aggregate age. ISTH, Boston, 2009.
124. Speich, H.E., Caughran, J.D., Lands, L.T., **Jennings, L.K.** Dispersal of platelet aggregates by P2Y12 antagonist ARC-69931MX. ISTH, Boston, 2009.
125. Kotha, J., Hill, S.N., Grgurevich S., Cholera, S. **Jennings, L.K.** CD9 tetraspanin is a repressor of GPIIb-IIIa activation. ISTH, Boston, 2009.
126. Gibson, C.M., Mega, J., **Jennings, L.K.**, Braunwald, E., Sun, X., Plotnikov, A.N., Zolynas, R., Lee, M., Notani, R., Misselwitz, F., Peters, G., and Burton P. Effect of rivaroxaban on F1.2 concentration in patients with acute coronary syndrome: An ATLAS ACS TIMI 46 substudy. AHA, 2009.
127. Gibson, C.M., Mega, J., **Jennings, L.K.**, Braunwald, E., Sun, X., Plotnikov, A.N., Zolynas, R., Lee, M., Notani, R., Misselwitz, F., Peters, G., and Burton P. Effect of rivaroxaban on prothrombin time and prothrombinase induced clotting time in patients with acute coronary syndrome: An ATLAS ACS TIMI 46 substudy. AHA 2009.
128. Caughran A., Henderson K., Speich H.E., **Jennings L.K.** Effects of P2Y12 Blockade on Platelet Aggregate Stability. Alpha Omega Alpha – St. Jude Children’s Research Hospital Lectureship and Medical Student Poster Session, Memphis, 2009.
129. Speich H.E., Earhart A.D., Hill S.N., Kueter T.J., White M.M., **Jennings L.K.** Platelet aggregate reversal by GPIIb-IIIa antagonists: Dependence on agonist and aggregate age. 2nd Annual UTHSC Postdoctoral Research Day, Memphis, 2009.
130. **Jennings, L.K.**, Kotha, J., Herr, M. CD9 regulates arterial smooth muscle cell morphology and alters contractile protein and MMP-9 expression. AHA, Chicago, 2010.
131. Speich H.E., Caughran J., Lands L., and **Jennings, L.K.** Dispersal of preformed platelet aggregates by the P2Y12 antagonist cangrelor. Alpha Omega Alpha – St. Jude Children’s Research Hospital Lectureship and Medical Student Poster Session, Memphis, 2011.
132. Jennings, J.A., Speich, H.E., **Jennings, L.K.**, Noel, S.P., Bumgardner, J.D., Haggard, W.O. Effects of Local Delivery of Antibiotics from Chitosan Constructs on Hemostasis. Annual Meeting of the Society for Biomaterials, Orlando, 2011.
133. Speich, H.E., Lands, L.T., Furman, R.R., Moodie, G.D., **Jennings, L.K.** Local concentrations of GPIIb-IIIa antagonists intensifies platelet thrombus instability. AHA, Orlando, 2011.

**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

134. **Jennings, L.K.**, White, M.M., Cholera, S., and Tyagi, A., Reversible blockade of GPIIb-IIIa reduces platelet storage lesions. ISTH, Amsterdam, 2013.
135. **Jennings, L.K.**, Hill, S., Herr, M., Grgurevich, S., and Kotha, J. Tetraspanin CD9 negatively regulates thrombus formation and stability and GPIIb-IIIa outside-in signaling. ISTH, Amsterdam, 2013.
136. Kotha, J. and **Jennings, L.K.** Standardization of flow cytometry methods for platelet surface receptor quantification in clinical studies. Molecular Med Tri-Con, San Francisco, CA, 2013
137. Kotha, J. and **Jennings, L.K.** The vasodilator-stimulated phosphoprotein assay as a companion test to assess P2Y12 receptor activity in clinical studies. Molecular Med Tri-Con, San Francisco, CA, 2013.
138. Lu, G., Kotha, J., Cárdenas, J.M., Herr, M.J., Pandey, A., Curnutte, J.T., Conley, P.B., and **Jennings, L.K.** In vitro characterization of Andexanet alfa (PRT064445), a specific fXa inhibitor antidote versus Aripazine (Per977), a non-specific reversal agent. AHA, November, Chicago, 2014.
139. **Jennings, L.K.**, Kotha, J., Cardenas, J., Herr, M., Bhal, V. Dixon, M., White, M., Combe, S., and Godfroid, E. Evaluation of the effects of a novel contact pathway inhibitor, Ir-cpi, on in vitro platelet function and coagulation. ISTH, Toronto, June, 2015.
140. **Jennings, L.K.**, Bhal, V., Herr, M., Dixon, M., Akins, S. Hord, E., Seiffert, D. Kotha, J. An in vitro transfusion model for the assessment of platelet function recovery following exposure to triple anti-platelet agents. ISTH, Toronto, June, 2015.
141. DeRaad, R., **Jennings, L.K.**, Hord, E., Walder, J.S. Antiplatelet effects of ticagrelor versus clopidogrel in Native American patients with stable coronary artery disease. American Heart Association, Orlando, FL, T4009, 2015.
142. Dunphy P.S., Kotha J.P., Dixon M., Jalenak, J.M., **Jennings, L.K.** Parstatin mediates platelet activation that is unaffected by PAR antagonism. American Society of Hematology, Orlando, FL, 2015.
143. Kotha, J.P., Dixon, M.L.A., Jalenak, J.M., Dunphy, P.S., Tcheng, J.E., Saucedo, J.F., and **Jennings, L.K.** Dynamic regulation of aggregate formation and stability in response to platelet inhibition via GPIIb-IIIa vs. P2Y12. Accepted for presentation, Cardiovascular Research Technologies, Washington, DC, February 2016.
144. **Jennings, L.K.**, Chen, X., Fabian, T.C., Yang, G., Diamond, M., Best, B.R., and Schulz, O. A Novel polypropylene (PP) hernia mesh with sustained anti-microbial drug delivery. Accepted for presentation, American Hernia Society, Washington, DC, April 2016.
145. **Jennings, L.K.**, Schulz, O, Chen, X., and Butcher, J. Polypropylene (pp) hernia mesh with sustained antibiotic drug delivery shows no evidence of mutagenicity, toxicity, or irritant activity up to 26 weeks of implantation. American Hernia Society, Cancun, Mexico, March 2017.
146. **Jennings, L.K.**, Schulz, O, Chen, X., Best, B. and Butcher, J. Mid-weight polypropylene hernia mesh with extended-release antibacterial activity against MRSA for > 14 days. Abdominal Wall Reconstruction, Washington, DC, June 7-10, 2017. First Place - abstract oral presentation.
147. **Jennings, L.K.** and Curry, B.J. The role of platelets in hemocompatibility of medical devices. BloodSurf 2017, Invited Faculty, Clemson University, Sept. 2017.
148. Kotha, J., Cardenas, J., Roe, M.T., Ohman, E.M. Gibson, C.M., and **Jennings, L.K.** Synergistic effects of rivaroxaban with direct-acting anti-platelet agents on platelet reactivity and thrombin generation. AHA, Anaheim, Nov. 2017.



**Lisa K. Jennings, Ph.D.**  
**Curriculum Vitae**

149. **Jennings, L.K.**, Kotha, J., Cohen, A.T., and Curnutte, J.T. Impact of d-dimer assays performed at local labs vs. central laboratory in the evaluation of APEX trial outcomes. ASH, Atlanta, 2017.
150. Dixon, M., Kotha, J., **Jennings, L.K.** Assessment of platelet count standardization in platelet-rich plasma for platelet function testing by light transmission aggregometry. ISTH, Dublin, 2018.
151. Connolly, T.M., Chintala, M., Peters, G., **Jennings, L.K.**, Kotha, J.P. The effect of JNJ The Effect of JNJ-64179375 on Coagulation Tests with Different Coagulation Analyzers. ISTH, Dublin, 2018.
152. **Jennings, L.K.** Pleiotropy of antiplatelet agents: Impact on IR injury. 3<sup>rd</sup> Maastricht Consensus Conference on Thrombosis (MCCT), 13-15 February 2019.
153. Bhatt, D.L., Pollack, Jr., C.V., Weitz, J.I., **Jennings, L.K.**, Lee, J. First Human Experience with a Ticagrelor Reversal Agent, NCT03492385. Amer. Coll. Cardiol (ACC), March 2018, New Orleans, LA.
154. **Jennings, L.K.**, Curry, B.J., Bhatt, D.L., Pollack, Jr., C.V., Weitz, J.I., Xu, S., Lee, J. Evaluation of the Pharmacodynamics of a Ticagrelor Reversal Agent PB2452. European Society of Cardiology (ESC), August 2019.
155. Franchi, F., Rollini, F., Faz, G., ..., **Jennings, L.K.**, Bass, T. and Angiolillo, D.J. Adjunctive vorapaxar therapy in patients with prior myocardial infarction treated with newer generation p2y12 receptor inhibitors prasugrel and ticagrelor (VORA-PRATIC): a prospective, randomized, pharmacodynamic study. American Heart Association, November 2019.
156. Kotha, J., Zhai, X., Herr, M., Hill, S., and **Jennings, L.K.** Tetraspanin CD9 regulates GPIIb-IIIa-mediated platelet function: Identification of unique protein interactomes. ISTH, Milan, Italy, 2020.
157. Curry, B.J., Kotha, J., Miller, L., Dixon, M., Herr, M.J., Dragutsky B., Bhula, R., McGrew, F. III, and **Jennings, L.K.** Ex vivo synergistic effects of apixaban with dual anti-platelet therapy (DAPT) in lowering platelet reactivity and thrombin generation (SEARCH). European Society of Cardiology (ESC), August 2020.
158. Cardenas, J., Kotha, J., Lu, G., Conley, P.B., Matthieu Bourdin, M., Herve, T. and **Jennings, L.K.** Validation of a modified anti-FXa assay on STA- Compact Analyzer for measuring FXa inhibitor levels in the presence of Andexanet alfa. ASH, San Diego, CA, 2020.
159. Cardenas, J., Kotha, J., Kotha, S., Graham, M., Lambert, S., Hew, K, **Jennings, L.K.** Development and validation of a flow cytometric assay for measuring glycoprotein A repetitions predominant protein GARP target engagement by ABBV-151. American Association for Cancer Research (AACR), Virtual Meeting, 2021.
160. Curry, B.J., Brown, R.J., Bhatt, D.L., Arnold, S.E., Lee, J.S., and **Jennings, L.K.** Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: Impact of hematocrit and generic versions of ticagrelor in vitro. Moderated Poster, European Society of Cardiology, Barcelona, Aug 25- 29, 2022.
161. Alleman, R.K., McGrew, F.A., Kotha, J., Angiolillo, D.J., Jefferies, J.L., and **Jennings, L.K.** Cross-sectional, exploratory assessment of biomarkers in patients with decompensated heart failure and underlying coronary artery disease (ABIDE-HF). Accepted, poster presentation, AHA, 2022.

**Patents**

- #8,236,338 Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts, Abul-Khoudoud, et al: August 7, 2012
- #8,568,763 Compositions and coatings for delivery of therapeutic agents, Abul-Khoudoud, et al: October 29, 2013

## **Lisa K. Jennings, Ph.D.**

### **Curriculum Vitae**

- #9,125,970 Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts, Abul-Khoudoud, et al: September 8, 2015
- #9,605,175 Polymer coating compositions and coated products, Jennings et al: March 28, 2017
- #10,314,912 Polymer coating compositions and coated products, Jennings et al: June 11, 2019
- #10,729,820 Methods and processes for application of drug delivery polymer coatings, Jennings et al: August 4, 2020
- # GB2528421 Methods and processes for application of drug delivery polymeric coating

#### **Academic Activities and Committees**

- Operational Strategic Plan Research Committee, UTHSC 2015 – present
- Member, Dean's Advisory Board, College of Arts and Sciences, The University of Memphis, 2014 – present
- Chair, 16th MidWest Platelet Conference, October 2017
- Chair, College of Graduate Health Sciences Alumni Advisory Board, UTHSC, 2019 – present
- Apprenticeship Lecture, Herff College of Engineering, University of Memphis, April 2021
- Chair, Dean's Advisory Board, College of Arts and Sciences, The University of Memphis, 2021-
- Mentor, Entrepreneurship for Biomedicine (E4B) Training Program, Washington University School of Medicine, 2022
- Search Committee, UTHSC, 2022

#### **Community Organizations and Activities**

##### Non-Profit Organizations

- Board of Directors, American Heart Association, Shelby County Division, 2001-2006
- Volunteer, American Heart Association
- President, American Heart Association, Shelby County Division, 2003-04
- Member, Grant Review Committee, Women's Foundation of Memphis, 2003-2006
- Co-Chair, Local Grants Committee, Women's Foundation of Memphis, 2005
- President's Club, University of Tennessee
- Volunteer, MIFA, Meals-on-Wheels, 2009-2010
- Judge, 5th Annual Scipreneur Challenge, Memphis, TN 2021

##### Community Organizations

- Kiwanis Club of Memphis, 2000-2007
- Kiwanis Club of Memphis, Program Committee, 2000-2005
- Board of Directors, Kiwanis Club of Memphis, 2001-2005
- President-Elect, Kiwanis Club of Memphis, 2002-03
- President, Kiwanis Club of Memphis, 2003-04

##### COMMUNITY HONORS

- 50 Women Who Make A Difference, Memphis, TN 2001
- State of Tennessee House of Representatives Certificate of Recognition, 2001
- City of Memphis, Certificate of Recognition, 2001
- Women's Foundation For a Greater Memphis Tribute, 2002
- Girls, Inc., She Knows Where She is Going, 2003
- Women of Achievement, Initiative Award, 2012
- Finalist, Small Business CEO of the Year, 2012
- Inside Memphis, Innovation Award, 2015

## **Lisa K. Jennings, Ph.D.**

### **Curriculum Vitae**

- Memphis Business Journal, Health Care Heroes, Innovation Award, 2018
- Top Tiger Award, University of Memphis, 2019
- Patriotic Employer Award, from the Employer Support of the Guard & Reserve (ESGR), Department of the US Department of Defense, 2019

#### **FEATURED ARTICLES AND VIDEO**

- Commercial Appeal, 1999
- UTHSC Medicine, 1999
- Commercial Appeal, 2000
- UTHSC Medical Alumnus, 2000
- Physician's Practice, August 2000
- Tennessee Alumnus, Summer 2001
- Memphis Woman Magazine, 2001
- Women's Foundation, Everyday HEROes, 2002
- Memphis Woman, 2002
- MidSouth Wellness Guide, 2003
- Memphis Business Journal, 2004
- Best of Times, February, 2005
- CNN News, 2007
- Memphis Business Journal, 2010
- Crossroads, Memphis Chamber of Commerce, 2011
- CNBC, Feature Program on Fed Ex/UPS Global Shipping "Package Wars", 2012
- Memphis Business Journal, 2012
- Memphis Business Quarterly, 2013
- UTHSC Medicine, 2014
- Commercial Appeal, 2015
- Memphis Business Journal, 2015
- MedTech Intelligence, 2016
- News-Medical, 2016
- OnlineTMD.com, 2016
- Memphis Business Journal, 2016
- Commercial Appeal, 2017
- Health Care Heroes, Memphis; Innovation Award, 2018
- Inside Memphis Business, 2018
- Greater Memphis Medical Device Council, Journal and Directory, 2019
- Memphis Business Journal, 2020
- UTHSC College of Graduate Health Sciences 2022